Neurocrine Biosciences (NBIX) analyst forecast and price target
Analyst forecast
Consensus of 30 analyst ratings
Based on 15 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Morgan Stanley | Maintained | Equal-Weight | $182.00 from $196.00 | Aug 13, 2026 |
| Wedbush | Maintained | Outperform | $194.00 from $185.00 | Aug 3, 2026 |
| Truist Securities | Maintained | Buy | $213.00 from $200.00 | Aug 3, 2026 |
| Canaccord Genuity | Maintained | Buy | $210.00 from $200.00 | Aug 3, 2026 |
| Needham | Maintained | Buy | $204.00 from $200.00 | Jul 31, 2026 |
| Stifel | Maintained | Buy | $215.00 from $188.00 | Jul 31, 2026 |
| Guggenheim | Maintained | Buy | $222.00 from $200.00 | Jul 31, 2026 |
| Piper Sandler | Maintained | Overweight | $210.00 from $207.00 | Jul 31, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $215.00 from $210.00 | Jul 31, 2026 |
| TD Cowen | Maintained | Buy | $220.00 from $200.00 | Jul 31, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $196.00 from $193.00 | Jul 31, 2026 |
| RBC Capital | Maintained | Outperform | $198.00 from $195.00 | Jul 31, 2026 |
| Citigroup | Maintained | Buy | $249.00 from $246.00 | Jul 31, 2026 |
| Guggenheim | Maintained | Buy | $200.00 from $175.00 | Jul 21, 2026 |
| Wells Fargo | Maintained | Overweight | $200.00 from $175.00 | Jul 17, 2026 |
| Truist Securities | Maintained | Buy | $200.00 from $155.00 | Jul 13, 2026 |
| BMO Capital | Maintained | Market Perform | $170.00 from $144.00 | Jul 13, 2026 |
| RBC Capital | Maintained | Outperform | $195.00 from $183.00 | Jul 7, 2026 |
| Goldman Sachs | Maintained | Buy | $213.00 | Jun 2, 2026 |
| RBC Capital | Maintained | Outperform | $183.00 from $180.00 | May 29, 2026 |
Frequently asked questions
What is the price target for NBIX stock?
The average 12-month analyst price target for Neurocrine Biosciences (NBIX) is $207.67, with a high estimate of $249.00 and a low of $170.00, across 15 analysts.
Is NBIX a buy, sell, or hold?
Analysts covering Neurocrine Biosciences currently average a Buy rating: 27 buy, 3 hold and 0 sell, from 30 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for NBIX?
The average price target of $207.67 implies 34.89% upside from the last price of $153.95.
What is the latest analyst rating on NBIX?
On Aug 13, 2026, Morgan Stanley maintained Neurocrine Biosciences at Equal-Weight with a price target of $182.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.